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A B S T R A C T
Background: Vitamin D deﬁciency is a frequent pathology associated with cardiovascular diseases and
physical performance.
Objective: To study the link between 25-hydroxyvitamin D (25OHD) level and physical performance and
gain in physical performance after cardiovascular rehabilitation (CVR) with vitamin D deﬁciency.
Methods: 25OHD level was assessed in a retrospective cohort of patients admitted for CVR. Data were
collected on physical ﬁtness [6-min walk test distance (6MWD) in percentage of predicted, maximal
power (Pmax)]. The threshold of vitamin D deﬁciency was 20 ng/ml chosen according to the literature.
Results: Among the 131 patients included, as compared with those with nondeﬁciency (n = 83; 63%),
patients with vitamin D deﬁciency (n = 48, 37%) had lower initial 6MWD (82  18 vs 89  12% predicted,
P = 0.009) and Pmax (100  58 vs 120  39 W, P = 0.006). After CVR, this difference was maintained. The
improvement in 6MWD and Pmax was signiﬁcantly lower with deﬁciency than nondeﬁciency, for an increase
of 11  8% versus 14  9% predicted (P = 0.048) and 10  30 versus 32  30 W (P = 0.00001), respectively.
Conclusion: Vitamin D deﬁciency may be associated with impaired physical ﬁtness before CVR and a
smaller gain in physical ﬁtness with CVR, probably related to the action of vitamin D on the muscle.
 2016 Published by Elsevier Masson SAS.
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Vitamin D deﬁciency is a frequent pathology, with about 30%
deﬁciency in the United States [1,2] and 36.7% in France in the
overall population [3]. The hormone has an important role in
regulating body levels of calcium and phosphorus and in bone
mineralization [4]. However, it also has a pleiotropic action on the
whole body, including neuromuscular, cardiovascular [5], immune
and regulation systems, via nongenomic and genomic effects [4].
Much epidemiological data suggests that cardiovascular disease
(CVD) and mortality from CVD seem to be associated with vitamin
D deﬁciency [1,5–7] Moreover, most [8] but not all [9,10] studies
have shown the beneﬁcial effect of vitamin D status on physical
performance. Vitamin D status and physical performance are
associated with deﬁciency in older adults, who have lower mobility,
daily life abilities (walking, stand, balance), handgrip and quadriceps
femoris strength and more falls [5,11–13]. Toffanello et al. found low* Corresponding author. Unite´ de re´adaptation cardiaque ambulatoire, CHU
Toulouse Rangueil, 1, avenue Jean-Poulhe`s, TSA 50032, 31059 Toulouse cedex,
France. Tel.: +33561321681.
E-mail address: labrunee.m@chu-toulouse.fr (M. Labrunee).
http://dx.doi.org/10.1016/j.rehab.2016.01.012
1877-0657/ 2016 Published by Elsevier Masson SAS.25-hydroxyvitamin D (25OHD) levels signiﬁcantly associated with
worse coordination in women and weak strength and aerobic
capacity (6MWD) in both genders [14]. Focusing on the CVD
population, Boxer et al. showed an association between 25OHD level
and 6MWD and peak maximal volume of oxygen (VO2) in heart
failure patients [15] but no change from baseline to 6 months with
25OHD supplementation (50,000 IU/placebo/week) but without
speciﬁc exercise training [16].
Here, we aimed to assess in a French heart disease population the
association between 25OHD level and physical performance and
the improvement in physical performance after exercise training
in patients undergoing cardiovascular rehabilitation (CVR). We used
2 primary endpoints: the 6MWD in percentage of predicted normal
value (% predicted) and maximal power (Pmax) in Watts.
2. Materials and methods
2.1. Study design and population
The study was an observational, noninterventional, retrospec-
tive, open, monocentric study from January 2012 to July 2013
Table 1
Patient characteristics by vitamin D deﬁciency and nondeﬁciency.
Deﬁcient
(n = 83)
Nondeﬁcient
(n = 48)
P value
Age (years) 55  12 57  13 ns
Gender (male/female) 8/2 9/1 ns
Weight (kg) 76  25 79  16 ns
Cardiovascular diseases
Systolic heart failure (%) 49.40 54.20 ns
Ischemic cardiopathy (%) 74.70 87.50 ns
Nonischemic cardiopathy (%) 16.90 10.40 ns
Valvular cardiopathy (%) 8.40 2.10 ns
25 (OH) vitamin D3 level (ng/ml) 12  7 27  8 P < 0.001
ns: nonsigniﬁcant difference.
Table 2
Physical performance measurements before and after cardiovascular rehabilitation
for patients with vitamin D deﬁciency and nondeﬁciency.
Measurements Deﬁcient
(n = 83)
Nondeﬁcient
(n = 48)
P value
Initial
6MWD 82  18 89  12 0.009
Pmax 100  58 120  39 0.006
Final
6MWD 93  18 103  13 0.001
Pmax 110  68 152  40 0.00001
Gain
6MWD 11  8 14  9 0.048
Pmax 10  30 32  30 0.00001
6MWD: 6-min walk test distance (% predicted); Pmax: maximal power (W).
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deﬁciency. Patients already taking vitamin D supplements or with
osteoarticular limitations were excluded. Eligible participants were
recruited from a CVR unit in Rangueil Hospital in Toulouse. The
protocol was approved by the local ethical committee and all
subjects gave their informed consent to participate.
2.2. Exercise program
All patients performed a 20-session CVR program, 4 sessions
per week. Each session included 40 min of aerobic exercise on a
cycloergometer or treadmill continuously monitored, under
medical supervision and followed by muscle strengthening
supervised by a physiotherapist. Exercise intensity was deter-
mined according to the heart rate of the aerobic ventilation
threshold during an initial test of maximal exercise capacity.
Intensity was increased progressively according to the patient’s
tolerance.
2.3. Assessment of outcomes
All patients underwent echocardiography before beginning CVR
with left ventricular ejection fraction (LVEF) measurement to
evaluate heart failure prevalence (LVEF < 45%). LVEF was calcu-
lated as the percentage ratio of the difference between end-
diastolic and end-systolic volume to the end-diastolic volume
according to the Simpson biplane method [17,18]. 25OHD level
was assessed in a cohort of 131 patients admitted to CVR. 25OHD
level in blood samples was assessed before any vitamin D
supplementation. The threshold of vitamin D deﬁciency was
20 ng/ml according to the literature [6].
Primary endpoints were parameters of physical ﬁtness (6MWD,
Pmax) collected at the beginning and end of CVR. Gain in
performance was deﬁned as the difference between the initial
and the last measurement. 6MWD was measured then calculated in
% predicted according to age, gender, height and weight with the
equation [7.57  height (cm)][5.02  age (years)][1.76  weight
(kg)]309 for men, [2.11  tall (cm)][5.78  age (years)]
[2.29  weight (kg)] + 667 for women. Ambulatory patients on
the ﬁrst day of CVR underwent functional capacity evaluation by
the 6MWD test repeated once. Tests were performed on a ﬂat,
straight, indoor 25 m course under physiotherapist supervision.
Additionally, patients were measured for maximal exercise capacity
on a cycloergometer (JAEGER ER 900) 2 days before CVR, beginning
at 20 W with a 10 W increase every minute until maximum
performance [19]. Reasons for stopping a test were electrocar-
diographic modiﬁcations (severe ST segment depression > 3 mm
or frequent ventricular extrasystoles), increase in blood pressure
(systolic > 260 mm Hg, diastolic > 130 mm Hg), or symptoms
(severe fatigue, chest pain, dyspnoea, or dizziness) [19].
At the end of the 20 sessions of CVR, patients performed a ﬁnal
6MWD test and a ﬁnal exercise test on the cycloergometer.
Evaluations were performed under the same conditions: by same
examiner and on the same cycloergometer.
2.4. Statistical analysis
Data were analyzed by use of SPSS 15 (SPSS Inc., Chicago, IL,
USA). Normality was assessed by the Kolmogorov-Smirnov test.
Data are described as mean  SD for quantitative data and median
(interquartile range) for qualitative data. We compared initial
characteristics between vitamin D-deﬁcient and nondeﬁcient
patients by Student’s t test for normally distributed variables and
Wilcoxon-Mann-Whitney test for nonnormally distributed variables.
Proportions were compared by chi-square test or Fisher’s exact test.
P < 0.05 was considered statistically signiﬁcant.3. Results
We included 131 patients undergoing CVR from January 2012 to
July 2013: 63% (n = 83) were vitamin D-deﬁcient and 37% (n = 48)
not deﬁcient and did not differ in sociodemographic and
anthropometric characteristics (Table 1). The mean age was
55  12 versus 57  13 years (P > 0.05) and mean weight
79  16 versus 76  25 kg (P > 0.05); 19.3% versus 10.4% were
female. In total, 74.7 and 87.5% had ischemic cardiomyopathy,
16.9 and 10.4% dilated cardiomyopathy, 8.4 and 2.1% valvular
cardiomyopathy and 49.4 and 54.2% congestive heart failure. The
mean serum vitamin D levels were 12.0  7.0 versus 27.0  7.5 ng/ml
(P < 0.0001).
Initial 6MWD results for vitamin D-deﬁcient and –nondeﬁcient
patients were 82  18% and 89  12% predicted (P = 0.009) and
initial Pmax was 100  58 and 120  39 Watt (P = 0.006) (Table 2).
After CVR, this difference was maintained, with 6MWD at
93  18 versus 103  13% predicted (P = 0.001) and Pmax at
110  68 versus 152  40 W (P = 0.00001). The improvement in
6MWD and Pmax was lower with deﬁciency than nondeﬁciency:
11  8 versus 14  9% predicted (P = 0.048) and 10  30 versus
32  30 W (P = 0.00001) (Fig. 1).
4. Discussion
Our study suggests that vitamin D deﬁciency may be associated
with decreased physical ﬁtness and a lesser response to physical
training in heart failure patients undergoing CVR.
Although our study was not tailored to assess the prevalence of
vitamin D deﬁciency, we found that the deﬁciency might concern
some patients during CVR programs. Interestingly, the level of
vitamin D deﬁciency we found (63%) is similar to the literature for
CVD patients. Pilz et al. found 65% deﬁciency among 3000 patients
with coronary angiography, but the 2000–2004 NHANES (US
National Health and Nutrition Examination Survey) found about
30% deﬁciency. The 2006–2007 ENNS (French Nutrition and Health
Survey) found 36.7% deﬁciency [3] in the overall population.
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Fig. 1. Improvement in 6 min walk test distance (6MWD; % predicted) and maximal
power (Pmax) after cardiovascular rehabilitation for patients with vitamin D
deﬁciency and nondeﬁciency. *P < 0.05.
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ﬁtness at entry into a CVR program is similar to the Toffanello et al.
results. Boxer et al. also found increased 6MWD and VO2
associated with increased vitamin D level in 66 heart failure
patients with LVEF < 40% [15]. However, the authors found no
change from baseline to 6 months after supplementation with
25OHD 50,000 IU/placebo/week for peak VO2, 6MWD, timed up
and go test, and isokinetics [16] Therefore, the links between
vitamin D level and physical ﬁtness are unclear.
In the literature, we found many experimental arguments to
support a positive effect of vitamin D on physical performance. Part
of the explanation is that 1,25 vitamin D is involved in modulating
and maintaining heart cell structure and function via a vitamin D
receptor (VDR). For example, the vitamin affects the growth,
proliferation and morphology of murine cardiomyocytes (HL-1
cells) [5,21]. Moreover, 25OHD level is associated with left
ventricular thickness and LVEF in heart failure subjects. Ameri
et al. showed signiﬁcantly increased LV end-diastolic and end-
systolic diameters and LV end-diastolic and end-systolic volumes
in heart failure patients with 25OHD level < 25 nmol/L [22]. From
a vascular point of view, vitamin D has an impact on regulating
smooth muscle cell growth, thrombogenicity, ﬁbrinolysis and
endothelial regeneration [23]. Sypniewska et al. showed a relation
between 25OHD3 and arterial wall thickness and stiffness, and
systolic and diastolic blood pressure in 158 patients from the
general population [24]. Finally, 25OHD is associated with
peripheral muscle changes; it increases muscle cell contractility
in animals [25] and shows modiﬁcations on histology. Vitamin D
supplementation increases intramyonuclear VDR concentration in
type II ﬁbers, type II muscle ﬁber diameter and percentage of type II
ﬁbers [25,26]. Of interest, type II muscle ﬁbers are the ﬁrst to be
recruited for short intense exercises such as preventing a fall. In
brief, the lesser physical ﬁtness and smaller gain after CVR with
vitamin D deﬁciency than nondeﬁciency could result from several
mechanisms related to the action of vitamin D on muscles and the
CV system that determine adaptation to physical exercise.
Many questions remain concerning the exact causality role of
vitamin D because most of but not all studies found that vitamin D
supplementation did not improve functional capacity in CVD
[15,23]. For example, Amin et al. found that restoration of 25OHD
level after 4 months of supplementation was associated with
improved NYHA class (P < 0.001) and 6MWD (P < 0.001) and
decreased probone natriuretic protein level (P < 0.001) in 100 heart
failure patients [27]. However, Witham et al., in a randomized,
parallel group, double-blind, placebo-controlled trial, followedpatients with heart failure  70 years old with 25OHD
level < 50 nmol/L (20 ng/ml) receiving 100,000 U oral vitamin
D2 or placebo at baseline and 10 weeks. 6MWD did not improve in
the treatment group relative to the placebo group. No signiﬁcant
beneﬁt was seen on timed up and go testing, subjective measures
of function, and daily activity [28].
Vitamin D deﬁciency could also be an indicator of CVD severity,
and therefore continuing CVR for deﬁcient patients after supple-
mentation would be of interest. Comparisons could be made with
diabetic coronary patients with lesser improvement after CVR and
those without diabetes [29] Vitamin D normal level may be
necessary but not sufﬁcient to improve physical ﬁtness because
our results showed less improvement with vitamin D deﬁciency.
Therefore, vitamin D supplementation and physical training
should be associated to better improve functional capacity.
The main limitation of our study is that it is a retrospective
work, which explains in part the missing data on calcium,
phosphorus and parathyroid hormone levels and 25OHD level
after supplementation or nutriment deﬁciency. We have showed
only an association, which does not mean causality. Confounding
factors such as seasonal impact, initial physical level and other
vitamin deﬁciency were not analyzed. Another limitation could be
that vitamin D deﬁciency may be associated with a particular
proﬁle with different habits of daily life, such as practising fewer
physical activities outside. Moreover, the relatively young age of
patients – 55  12 versus 57  13 years for deﬁcient and non-
deﬁcient patients, respectively, as compared with 58.6 for patients
under CVR in France [30] – could also have affected our results.
Finally, we have no data concerning vitamin D supplementation during
CVR or other nutriment deﬁciency. However, if supplementation was
initiated during CVR, this supplementation was not completely
achieved at the reevaluation, thereby limiting interferences with our
results. Patients perhaps might have changed their nourishment after
nutritional therapeutic education sessions, which could have affected
our results even if vitamin D recharge delay is longer [31].
Further study could investigate the potential synergic effects of
supplementation in vitamin D and training, to add an isokinetics
evaluation (muscular performance) and to take into account the
seasonal variation in vitamin D level as a possible confounding
factor.
5. Conclusion
Vitamin D deﬁciency may be associated with impaired physical
ﬁtness at entry into a CVR program for patients with heart failure,
with a smaller gain in physical ﬁtness after the program, probably
related to the known action of vitamin D on the muscle. More
studies need to be done.
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